Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,081 | 135 | 62.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,139 | 1 | 34.1% |
| Education | $120.04 | 3 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $1,246 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $394.97 | 28 | $0 (2024) |
| PFIZER INC. | $339.73 | 26 | $0 (2024) |
| Janssen Biotech, Inc. | $295.11 | 16 | $0 (2024) |
| Astellas Pharma US Inc | $128.93 | 7 | $0 (2024) |
| Foundation Medicine, Inc. | $120.27 | 2 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $72.92 | 4 | $0 (2024) |
| TAIHO ONCOLOGY, INC. | $70.50 | 5 | $0 (2024) |
| Mirati Therapeutics, Inc. | $66.59 | 4 | $0 (2024) |
| Eisai Inc. | $63.72 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $637.22 | 38 | PFIZER INC. ($162.57) |
| 2023 | $441.37 | 27 | Novartis Pharmaceuticals Corporation ($147.74) |
| 2022 | $336.54 | 23 | Novartis Pharmaceuticals Corporation ($206.23) |
| 2021 | $626.83 | 44 | PFIZER INC. ($120.43) |
| 2020 | $159.33 | 6 | Janssen Biotech, Inc. ($76.95) |
| 2018 | $1,139 | 1 | Incyte Corporation ($1,139) |
All Payment Transactions
139 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $8.48 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: ONCOLOGY | ||||||
| 12/03/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $6.19 | General |
| Category: Oncology | ||||||
| 11/16/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $35.33 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $26.45 | General |
| Category: Oncology | ||||||
| 10/23/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $16.78 | General |
| Category: Hematology/Oncology | ||||||
| 10/02/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $34.03 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/13/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $13.45 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.70 | General |
| Category: Oncology | ||||||
| 08/26/2024 | Genentech USA, Inc. | Polivy (Biological) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: BioOncology | ||||||
| 08/16/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Oncology | ||||||
| 08/13/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $10.92 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $27.96 | General |
| Category: Oncology | ||||||
| 07/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TALVEY, TECVAYLI | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Oncology | ||||||
| 07/16/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/26/2024 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $21.75 | General |
| Category: Oncology | ||||||
| 06/07/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $13.43 | General |
| Category: Oncology | ||||||
| 06/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $12.24 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $13.54 | General |
| Category: Hematology/Oncology | ||||||
| 05/07/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $12.04 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $13.07 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 961 | 25,602 | $459,489 | $143,122 |
| 2022 | 17 | 728 | 4,302 | $282,422 | $80,486 |
| 2021 | 18 | 686 | 1,724 | $128,824 | $51,855 |
| 2020 | 12 | 472 | 791 | $129,164 | $39,028 |
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 99 | 286 | $46,332 | $27,452 | 59.2% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 18 | 18 | $43,200 | $19,759 | 45.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 15 | 19,500 | $78,000 | $17,144 | 22.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 28 | 169 | $59,995 | $16,199 | 27.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 56 | 153 | $17,595 | $9,578 | 54.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 19 | 20 | $20,000 | $8,012 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 72 | 103 | $10,712 | $6,711 | 62.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 55 | 55 | $14,575 | $6,675 | 45.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 161 | 543 | $9,774 | $4,553 | 46.6% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 11 | 53 | $3,770 | $4,459 | 118.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 28 | 208 | $18,720 | $4,405 | 23.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 153 | 482 | $19,762 | $3,653 | 18.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 29 | 29 | $6,525 | $2,995 | 45.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $6,930 | $2,882 | 41.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 34 | 58 | $9,280 | $2,674 | 28.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 11 | 48 | $8,400 | $2,262 | 26.9% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 13 | 34 | $4,420 | $813.12 | 18.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 73 | $3,066 | $741.20 | 24.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 19 | 56 | $3,080 | $636.22 | 20.7% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 11 | 13 | $6,500 | $574.86 | 8.8% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 15 | 550 | $41,250 | $435.42 | 1.1% |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | Office | 2023 | 11 | 530 | $21,730 | $149.62 | 0.7% |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 2023 | 11 | 1,300 | $1,300 | $147.63 | 11.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 25 | 1,232 | $1,232 | $117.07 | 9.5% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 12 | 33 | $3,201 | $66.57 | 2.1% |
About Dr. Hiral Parekh, MD
Dr. Hiral Parekh, MD is a Internal Medicine healthcare provider based in Jacksonville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1508026782.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Hiral Parekh, MD has received a total of $3,340 in payments from pharmaceutical and medical device companies, with $637.22 received in 2024. These payments were reported across 139 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($2,081).
As a Medicare-enrolled provider, Parekh has provided services to 2,847 Medicare beneficiaries, totaling 32,419 services with total Medicare billing of $314,491. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology & Oncology
- Location Jacksonville, FL
- Active Since 06/11/2008
- Last Updated 09/23/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1508026782
Products in Payments
- IBRANCE (Drug) $138.01
- PROMACTA (Drug) $129.77
- FOUNDATIONONE (Device) $120.27
- IMBRUVICA (Drug) $112.35
- JAKAFI (Drug) $107.18
- DARZALEX (Biological) $101.09
- FEMARA (Drug) $83.76
- XOSPATA (Drug) $82.90
- XARELTO (Drug) $72.92
- LONSURF (Drug) $70.50
- KRAZATI (Drug) $66.59
- Lenvima (Drug) $63.72
- XTANDI (Drug) $63.04
- OXBRYTA (Drug) $59.43
- SCEMBLIX (Drug) $57.31
- KEYTRUDA (Biological) $56.91
- RYBREVANT (Drug) $47.40
- Vonjo (Drug) $40.58
- PIQRAY (Drug) $38.95
- INLYTA (Drug) $36.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Jacksonville
Siddharth Wayangankar, Md, MD
Internal Medicine — Payments: $1.3M
Dr. Alan Miller, M.d, M.D
Internal Medicine — Payments: $770,575
Kalina Sanders, M.d, M.D
Internal Medicine — Payments: $626,907
Jose Soto Soto, Md, MD
Internal Medicine — Payments: $576,809
Dr. Jennifer Fulton, Md, MD
Internal Medicine — Payments: $556,016
Dr. Francis Farraye, M.d, M.D
Internal Medicine — Payments: $504,399